Why Illumina (ILMN) Is Up 8.4% After Raising 2026 Outlook And Launching New Buybacks

Simply Wall St.06:19

In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633628689?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-05-05 06:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633628689","market":"hk","top_or_hot":-1,"title":"Why Illumina (ILMN) Is Up 8.4% After Raising 2026 Outlook And Launching New Buybacks","media":"Simply Wall St.","content":"<div>\n<p>In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/why-illumina-ilmn-is-up-84-after-raising-2026-outlook-and-la\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Illumina (ILMN) Is Up 8.4% After Raising 2026 Outlook And Launching New Buybacks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Illumina (ILMN) Is Up 8.4% After Raising 2026 Outlook And Launching New Buybacks\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-05 06:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/why-illumina-ilmn-is-up-84-after-raising-2026-outlook-and-la><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/why-illumina-ilmn-is-up-84-after-raising-2026-outlook-and-la\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AI","symbol_name":"C3.ai, Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/why-illumina-ilmn-is-up-84-after-raising-2026-outlook-and-la","article_id":"2633628689","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/why-illumina-ilmn-is-up-84-after-raising-2026-outlook-and-la","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2633628689","pubTimestamp":1777933190,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 revenue outlook of US$4.52–US$4.62 billion. \nAt the same time, the Board authorized a new US$1.5 billion share repurchase program on top of buybacks already reducing the share count by more than 7%, underscoring management’s confidence in the company’s financial position and demand trends.\nWith...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"AI":"C3.ai, Inc.","BK4543":"AI","BK4551":"寇图资本持仓","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","AIYY":"YIELDMAX AI OPTION INCOME STRATEGY ETF","BK4587":"ChatGPT概念","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4588":"碎股","AIPO":"Defiance AI and Power Infrastructure ETF","BK4528":"SaaS概念","BK4585":"ETF&股票定投概念","BK4023":"应用软件","AGIX":"通用人工智能 ETF-AGIX","BK4548":"巴美列捷福持仓","BK4534":"瑞士信贷持仓","BK4535":"淡马锡持仓","ILMN":"Illumina","BK4121":"生命科学工具和服务"},"translate_title":"为什么Illumina(ILMN)在上调2026年展望并启动新的回购后股价上涨8.4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARTY":0.61,"ILMN":1.5,"AGIX":0.61,"AI":0.61,"CHAT":0.61,"AIYY":0.6,"AIPO":0.61},"content_text":"In late April 2026, Illumina reported first-quarter results showing revenue of US$1.09 billion and net income of US$134 million, alongside higher earnings per share and an increased full-year 2026 revenue outlook of US$4.52–US$4.62 billion.  At the same time, the Board authorized a new US$1.5 billion share repurchase program on top of buybacks already reducing the share count by more than 7%, underscoring management’s confidence in the company’s financial position and demand trends. With Illumina raising 2026 guidance following stronger-than-expected Q1 results, we’ll examine how this could reshape the existing investment narrative. The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AdvertisementIllumina Investment Narrative RecapTo own Illumina, you need to believe that clinical sequencing and multiomics can support steady, recurring growth even as research and China remain uneven. The main short term catalyst is continued clinical uptake of platforms like NovaSeq X, while the biggest risk is that research funding softness and export restrictions weigh on instrument demand. The latest Q1 beat and modest guidance raise support the clinical story but do not fully resolve those demand and geopolitical concerns. The announcement that stands out most here is the new US$1.5 billion share repurchase authorization, on top of buybacks that have already reduced the share count by more than 7%. This move sits alongside higher 2026 revenue guidance of US$4.52–US$4.62 billion and stronger Q1 margins, reinforcing the role of capital returns and cost discipline as supporting catalysts if Illumina can sustain clinical growth and execution on its multiomics roadmap. Yet behind these positives, investors should be aware of how rising competition and regulatory scrutiny could still pressure... Read the full narrative on Illumina (it's free!)Illumina's narrative projects $5.0 billion revenue and $1.0 billion earnings by 2029. This requires 5.1% yearly revenue growth and about a $150 million earnings increase from $850.0 million today.Uncover how Illumina's forecasts yield a $136.11 fair value, in line with its current price.Exploring Other PerspectivesILMN 1-Year Stock Price Chart Some of the lowest target analysts were assuming revenue of about US$5.0 billion and earnings of roughly US$982 million by 2029, so compared with the recent guidance upgrade and stronger Q1 print, their view reflects a much more cautious stance on Illumina’s long term upside and reminds you that reasonable investors can look at the same numbers and reach very different conclusions.Explore 4 other fair value estimates on Illumina - why the stock might be worth as much as 15% more than the current price!Decide For YourselfDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your Illumina research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.Our free Illumina research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Illumina's overall financial health at a glance.Curious About Other Options?Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Outshine the giants: these 18 early-stage AI stocks could fund your retirement.Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633628689","isCrawlerRequest":true}